Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site

被引:116
作者
Steele, R. J. C. [1 ,2 ]
McClements, P. [3 ]
Watling, C. [3 ]
Libby, G. [2 ]
Weller, D. [4 ]
Brewster, D. H. [3 ]
Black, R. [3 ]
Carey, F. A. [5 ]
Fraser, C. G. [2 ]
机构
[1] Univ Dundee, Dept Surg, Dundee DD1 9SY, Scotland
[2] Kings Cross Hosp, Scottish Bowel Screening Ctr, Dundee, Scotland
[3] Natl Serv Scotland, Informat Serv, Edinburgh, Midlothian, Scotland
[4] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland
[5] Univ Dundee, Dept Pathol, Dundee DD1 9SY, Scotland
关键词
DEMONSTRATION PILOT; TRIAL; PERFORMANCE; MORTALITY; AGE;
D O I
10.1136/gutjnl-2011-300535
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Between 2000 and 2007, a demonstration pilot of biennial guaiac faecal occult blood test (GFOBT) screening was carried out in Scotland. Methods Interval cancers were defined as cancers diagnosed within 2 years (ie, a complete screening round) of a negative GFOBT. The stage and outcome of the interval cancers were compared with those arising contemporaneously in the non-screened Scottish population. In addition, the gender and site distributions of the interval cancers were compared with those in the screen-detected group and the non-screened population. Results Of the cancers diagnosed in the screened population, interval cancers comprised 31.2% in the first round, 47.7% in the second, and 58.9% in the third, although this was due to a decline in the numbers of screen-detected cancers rather than an increase in interval cancers. There were no consistent differences in the stage distribution of interval cancers and cancers from the non-screened population, and, in all three rounds, both overall and cancer-specific survival were significantly better for patients diagnosed with interval cancers (p<0.01). The percentage of cancers arising in women was significantly higher in the interval cancer group (50.2%) than in either the screen-detected group (35.3%, p<0.001) or the non-screened group (40.6%, p<0.001). In addition, the proportion of both right-sided and rectal cancers was significantly higher in the interval cancer group than in either the screen-detected (p<0.001) or non-screened (p<0.004) groups. Conclusions Although GFOBT screening is associated with substantial interval cancer rates that increase with screening round, the absolute numbers do not. Interval cancers are associated with a better prognosis than cancers arising in a non-screened population, and GFOBT appears to preferentially detect cancers in men and the left side of the colon at the expense of cancers in women and in the right colon and rectum.
引用
收藏
页码:576 / U132
页数:6
相关论文
共 24 条
  • [1] [Anonymous], SCOTTISH HLTH SURVEY
  • [2] Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial
    Atkin, Wendy S.
    Edwards, Rob
    Kralj-Hans, Ines
    Wooldrage, Kate
    Hart, Andrew R.
    Northover, John M. A.
    Parkin, D. Max
    Wardle, Jane
    Duffy, Stephen W.
    Cuzick, Jack
    [J]. LANCET, 2010, 375 (9726) : 1624 - 1633
  • [3] Gender differences in colorectal cancer: implications for age at initiation of screening
    Brenner, H.
    Hoffmeister, M.
    Arndt, V.
    Haug, U.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 96 (05) : 828 - 831
  • [4] Sex Differences in Performance of Fecal Occult Blood Testing
    Brenner, Hermann
    Haug, Ulrike
    Hundt, Sabrina
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (11) : 2457 - 2464
  • [5] Ascertainment of breast cancer by the Scottish Cancer Registry: An assessment based on comparison with five independent breast cancer trials databases
    Brewster, David H.
    Stockton, Diane L.
    [J]. BREAST, 2008, 17 (01) : 104 - 106
  • [6] Completeness of case ascertainment in a Scottish regional cancer registry for the year 1992
    Brewster, DH
    Crichton, J
    Harvey, JC
    Dawson, G
    [J]. PUBLIC HEALTH, 1997, 111 (05) : 339 - 343
  • [7] Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study
    Faivre, J
    Dancourt, V
    Lejeune, C
    Tazi, MA
    Lamour, J
    Gerard, D
    Dassonville, F
    Bonithon-Kopp, C
    [J]. GASTROENTEROLOGY, 2004, 126 (07) : 1674 - 1680
  • [8] Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
    Hardcastle, JD
    Chamberlain, JO
    Robinson, MHE
    Moss, SM
    Amar, SS
    Balfour, TW
    James, PD
    Mangham, CM
    [J]. LANCET, 1996, 348 (9040) : 1472 - 1477
  • [9] Randomised study of screening for colorectal cancer with faecal-occult-blood test
    Kronborg, O
    Fenger, C
    Olsen, J
    Jorgensen, OD
    Sondergaard, O
    [J]. LANCET, 1996, 348 (9040) : 1467 - 1471
  • [10] Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer
    Lindholm, E.
    Brevinge, H.
    Haglind, E.
    [J]. BRITISH JOURNAL OF SURGERY, 2008, 95 (08) : 1029 - 1036